Last Updated : May 6, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Advanced prostate cancer
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
Therapeutic Area: Stage IIB or IIC melanoma, adjuvant
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
Therapeutic Area: Relapsed or refractory diffuse large B-cell lymphoma
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation
Therapeutic Area: Relapsed or refractory multiple myeloma
Draft recommendations posted for stakeholder feedback: May 1, 2024
End of feedback period: May 16, 2024
Draft Recommendation